GET THE APP

Chemotherapy: Open Access

Chemotherapy: Open Access
Open Access

ISSN: 2167-7700

+44 1223 790975

Haiying Cheng

Haiying Cheng

United States

Publications
  • Short Communication
    New & Emerging Drugs for Squamous Cell Lung Cancer
    Author(s): Janaki Sharma and Haiying ChengJanaki Sharma and Haiying Cheng

    Lung Cancer is the leading cause of cancer-related death worldwide. Squamous cell lung cancer (SQCLC) is the second most common histology (20-30% of cases) among non-small cell lung cancers (NSCLC), yet the treatment options remain limited [1]. The current standard for first line treatment of advanced or metastatic SQCLC consists of mainly platinum based chemotherapy. Recently, necitumumab in combination with platinum based doublet therapy was approved as front-line therapy. Second line options until recently included docetaxel, gemcitabine, nab-paclitaxel and erlotinib. Now newer agents including afatinib, ramucirumab/docetaxel, nivolumab and pembrolizumab are also available with superior clinical benefits.. View More»
    DOI: 10.4172/2167-7700.1000178

    Abstract PDF

Relevant Topics

Top